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TRM, poor quality of life, graft versus host disease are sig-
niﬁcant risks of hematopoietic cell transplantation (HCT). In
addition to the risks of HCT, pre-transplant comorbidities
signiﬁcant impact transplant outcomes. A comparison of CCI
and HCT-CI revealed that HCT-CI was prognostic and better at
predicting TRM and overall OS. However, HCT-CI and CCI
have been inconsistent in validation studies. Patient het-
erogeneity in age, disease, disease-risk, comorbidities, and
conditioning regimens may limit their usefulness in UCB
recipients. The design of this research was to explore if HCT-
CI and/or CCI can accurately predict post-transplant out-
comes in the setting of uniform RIC UCB transplantation.
A retrospective chart review was performed on 87 consec-
utive UCB recipients receiving ﬂudarabine, cyclophospha-
mide, ATG, and 200 cGy TBI. GVHD prophylaxis was
cyclosporine and mycophenolate mofetil. Between 2005 and
2011, 87 patients age 19 e 71 (median 50) years, 51 males
(59%) and 36 females (41%), underwent RIC UCB trans-
plantation with the above regimen.
Most patients had advanced stage or high risk hematologic
malignancies; 56 hadMDS/AML (64%), 9 had ALL (10%), while
22 had other. Half of the patients were in CR > 2, with the
same number receiving more than 2 prior therapies.
14 patients had received a prior autologous HCT, 9 prior allo-
HCT, and three had failed a previous UCB transplantation. 14
patients failed to engraft. Median time to neutrophil
engraftment was 26 days (95% CI: 24 e 32 d), and to platelet
engraftment 39 days (95% CI: 31 e 71 d). No patient devel-
oped grade 4 acute GVHD. Grade 3 acute GVHD was seen in
15 / 87 patients (17%). Chronic GVHD was seen in 18 patients
(21%). To date 27 patients (31%) have relapsed. OS was 42%
and PFS was 37% at one year. Median PFS and median OS
were 9 months and 8 months, respectively (PFS 95% CI: 4 e
12 months, OS 95% CI: 5 e 13 months). Neither CCI, nor HCT-
CI were signiﬁcant predictors of OS and PFS, however ECOG
PS was signiﬁcantly associated with outcome (Table).
In a previous paper our group concluded that CCI performs
better than HCT-CI in elderly patients undergoing UCB, but
not in a population younger than 55 years. This pooled
analysis shows that we were unable to validate the generally
accepted prognostic indices. The majority of our patients
were in CR  2 and had very high risk disease. These factors
need to be taken into account in creating a new prognostic
index for UCB transplantation.PFS
yr p 1 yr 2 yr 4 yr p
% 0.029 28% 23% 10% 0.042
14% 8% 3%
% 0.129 34% 25% 9% 0.125
7% 6% 5%
0.238 28% 21% 6% 0.275
14% 10% 8%
ce status were correlated to TRM (p > 0.05). For ECOG PS, OR 0.9, p ¼ 0.86, CI
31 - 3.19.
